On July 30, 2021, Edwards Lifesciences Corporation, a California-based cardiac care and treatment company, disclosed in a quarterly filing with the US Securities and Exchange Commission that it had retained outside counsel and was conducting an investigation into whether “certain grants and other payments initiated by certain employees of the Company in Japan” may have violated the US Foreign Corrupt Practices Act. In its disclosure, Edwards stated that it had voluntarily notified the SEC and the US Department of Justice of the investigation, and that at the time of its filing it was not able to predict the outcome of the investigation or its potential impact on the Company’s financial statements. Edwards did not provide further detail.
August 1, 2021
Edwards Lifesciences discloses FCPA investigation
Related by Topic
New Post
Florida judge sentences reinsurance manager to 10 months’ time served for role in Ecuadorian bribery scheme
July 2, 2025
News Alert
New Post
Rising Cross-Border Enforcement Risk for Companies Operating in Latin America
June 26, 2025
Insight